T cell receptor beta variable 26 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored TRBV26 profile across patient tissues and cancer cell-line models. TRBV26 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRBV26 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, TRBV26 RNA expression shows 10,685 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where TRBV26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV26 survival associations across molecular data types. TRBV26 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV26 RNA expression–survival associations across cancer types. High TRBV26 expression shows unfavorable associations in UCEC, KIRC, STAD, PAAD, CESC and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TRBV26 RNA expression.
This table summarizes TRBV26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV26 shows higher tumor expression in KIRC. The KIRC box plot shows higher TRBV26 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .023).
This table shows molecular features associated with TRBV26 in patient tissues and cancer cell lines. In patient samples, TRBV26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
